hsCRP ≥2 mg/L

1 drugs

Predictive biomarker for patient selection in 6 indications

Approved Drugs

Indications

Companies

hsCRP ≥2 mg/L is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 6 indications including Hyperlipidemia, Atherosclerosis, Heterozygous Familial Hypercholesterolemia. Explore the targeted therapies, indications, testing methods, and companies developing hsCRP ≥2 mg/L drugs below.

Search hsCRP ≥2 mg/L Clinical Trials

Search recruiting trials on ClinicalTrials.gov

Drugs Targeting hsCRP ≥2 mg/L

Drug	Company	Therapeutic Area
ROSUVASTATIN CALCIUM	CHARTWELL RX	Metabolic

hsCRP ≥2 mg/L Indications

Hyperlipidemia Atherosclerosis Heterozygous Familial Hypercholesterolemia Homozygous Familial Hypercholesterolemia Primary Dysbetalipoproteinemia Hypertriglyceridemia

Companies with hsCRP ≥2 mg/L Drugs

CHARTWELL RX